MacroGenics Net Worth
MacroGenics Net Worth Breakdown | MGNX |
MacroGenics Net Worth Analysis
MacroGenics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including MacroGenics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of MacroGenics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform MacroGenics' net worth analysis. One common approach is to calculate MacroGenics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares MacroGenics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing MacroGenics' net worth. This approach calculates the present value of MacroGenics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of MacroGenics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate MacroGenics' net worth. This involves comparing MacroGenics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into MacroGenics' net worth relative to its peers.
Enterprise Value |
|
To determine if MacroGenics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding MacroGenics' net worth research are outlined below:
| MacroGenics had very high historical volatility over the last 90 days | |
| MacroGenics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 58.75 M. Net Loss for the year was (9.06 M) with loss before overhead, payroll, taxes, and interest of (62.47 M). | |
| MacroGenics currently holds about 133.74 M in cash with (78.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.18. | |
| MacroGenics has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Breast Cancer Therapeutics Global Market Research 2024 Advancements in Targeted and Immunotherapies Revolutionize Treatment - Forecasts to 2030 |
MacroGenics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in MacroGenics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to MacroGenics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know MacroGenics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MacroGenics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MacroGenics backward and forwards among themselves. MacroGenics' institutional investor refers to the entity that pools money to purchase MacroGenics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Investments Llc | 2024-09-30 | 883.4 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 882.7 K | Vestal Point Capital Lp | 2024-09-30 | 830 K | Northern Trust Corp | 2024-09-30 | 702.8 K | Pinnacle Associates Inc | 2024-09-30 | 688 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-09-30 | 661.9 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 566.3 K | Charles Schwab Investment Management Inc | 2024-09-30 | 492.8 K | Jane Street Group Llc | 2024-06-30 | 487.2 K | Bellevue Group Ag | 2024-09-30 | 9.9 M | Armistice Capital, Llc | 2024-09-30 | 6.3 M |
Follow MacroGenics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 215.91 M.Market Cap |
|
Project MacroGenics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.69) | (0.66) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.06) | (0.06) |
When accessing MacroGenics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures MacroGenics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of MacroGenics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in MacroGenics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MacroGenics. Check MacroGenics' Beneish M Score to see the likelihood of MacroGenics' management manipulating its earnings.
Evaluate MacroGenics' management efficiency
MacroGenics has return on total asset (ROA) of (0.2215) % which means that it has lost $0.2215 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6217) %, meaning that it created substantial loss on money invested by shareholders. MacroGenics' management efficiency ratios could be used to measure how well MacroGenics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.03 in 2024. Return On Capital Employed is likely to rise to -0.66 in 2024. At this time, MacroGenics' Other Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 245.6 M in 2024, whereas Total Assets are likely to drop slightly above 287.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.46 | 2.34 | |
| Tangible Book Value Per Share | 2.46 | 2.34 | |
| Enterprise Value Over EBITDA | 262.16 | 275.27 | |
| Price Book Value Ratio | 3.90 | 4.10 | |
| Enterprise Value Multiple | 262.16 | 275.27 | |
| Price Fair Value | 3.90 | 4.10 | |
| Enterprise Value | 528.8 M | 475.5 M |
Leadership effectiveness at MacroGenics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 0.4674 | Revenue 141.3 M | Quarterly Revenue Growth 9.648 | Revenue Per Share 2.264 | Return On Equity (0.62) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MacroGenics insiders, such as employees or executives, is commonly permitted as long as it does not rely on MacroGenics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MacroGenics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Koenig Scott over a month ago Disposition of 53265 shares by Koenig Scott of MacroGenics subject to Rule 16b-3 | ||
Koenig Scott over two months ago Acquisition by Koenig Scott of 374215 shares of MacroGenics subject to Rule 16b-3 | ||
Jeffrey Peters over three months ago Acquisition by Jeffrey Peters of 26250 shares of MacroGenics subject to Rule 16b-3 | ||
Jeffrey Peters over six months ago Acquisition by Jeffrey Peters of 13336 shares of MacroGenics subject to Rule 16b-3 | ||
Jeffrey Peters over six months ago Acquisition by Jeffrey Peters of 54376 shares of MacroGenics at 11.5 subject to Rule 16b-3 | ||
Jeffrey Peters over six months ago Disposition of 10875 shares by Jeffrey Peters of MacroGenics at 11.5 subject to Rule 16b-3 | ||
David Stump over a year ago Acquisition by David Stump of 19000 shares of MacroGenics subject to Rule 16b-3 |
MacroGenics Corporate Filings
8K | 21st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 20th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 5th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
MacroGenics Earnings per Share Projection vs Actual
MacroGenics Corporate Executives
Elected by the shareholders, the MacroGenics' board of directors comprises two types of representatives: MacroGenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MacroGenics. The board's role is to monitor MacroGenics' management team and ensure that shareholders' interests are well served. MacroGenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MacroGenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Karrels | CFO, Sr. VP and Corporate Secretary | Profile |
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.